Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Agenus Inc. (NASDAQ: AGEN) shares plunged 23.45 percent to close at $2.84 a share Thursday. The stock traded between $2.45 and $2.93 on volume of 2.75 million shares traded. The company announced that GlaxoSmithKline’s DERMA study did not meet its first co-primary endpoint. Shares of Agenus have fallen approximately 30.0 percent year-to-date.
Get more information on Agenus and free access to the in-depth equity report at:
www.FiveStarEquities.com/AGEN
Bazaarvoice Inc. (NASDAQ: BV) shares dropped 17.01 percent to close at $9.32 a share Thursday. The stock traded between $9.21 and $10.28 on volume of 4.24 million shares traded. The company reported GAAP net loss was $17.4 million for the first quarter of fiscal 2014, compared to a GAAP net loss of $18.5 million a year ago.
Get more information on Bazaarvoice and free access to the in-depth equity report at:
www.FiveStarEquities.com/BV
Nordion Inc. (NYSE: NDZ) shares spiked 4.46 percent to close at $8.20 a share Thursday. The stock traded between $7.95 and $8.26 on volume of 949,978 shares traded. The company reported revenues were $71.7 million for the third quarter of fiscal 2013, an increase of 7.0 percent when compared to a year ago. Shares of Nordion have gained approximately 27.0 percent year-to-date.
Get more information on Nordion and free access to the in-depth equity report at:
www.FiveStarEquities.com/NDZ
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares increased 8.07 percent to close at $3.48 a share Thursday. The stock traded between $3.12 and $3.49 on volume of 2.20 million shares traded. The company announced plans to focus resources on the completion of three lead clinical programs. Shares of Rigel Pharmaceuticals have fallen approximately 47.0 percent year-to-date.
Get more information on Rigel Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/RIGL
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com